UC Market Gets Increasingly Crowded – But High Unmet Need Remains
Ulcerative Colitis Market Snapshot
Executive Summary
Market Snapshot: The ulcerative colitis market looks set to experience strong pricing pressure over the next three to five years, with leading players losing exclusivity for their drugs and a flood of novel entrants set to hit the market.
You may also be interested in...
Theravance's Gut-Selective JAK Inhibitor Disappoints In Ulcerative Colitis Study
Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.
Rinvoq Shows Strong UC Efficacy, But Will JAK Ghosts Haunt It?
Safety appears balanced between the drug and placebo arms in upadacitinib’s third Phase III trial in ulcerative colitis, but there were low numbers of MACE and there are lingering safety concerns about the JAK class overall.
Pfizer's Xeljanz Post-Marketing Study Raises Safety Alarms
A safety study of Pfizer's anchor immunology brand Xeljanz showed higher rates of heart attacks and cancer versus a TNF inhibitor.